Table 2.
Age (y), mean (range) | Prevalence (%) | Progression (%) | De novo (%) | |
---|---|---|---|---|
MsOS (Hong Kong) Year 0a | 72.6 (65–98) | 25 | ||
MsOS (USA) Year 0b | 71.5 (65–89) | 43.1 | ||
MrOS (Hong Kong) Year 0c | 72.4 (65–92) | 19.1 | ||
MrOS (USA) Year 0d | 31 | |||
MsOS (Hong Kong) Year 4e | 75.7 (68–102) | 41.2 | 16.5 | 12.7 |
MrOS (Hong Kong) Year 4f | 75.5 (68–95) | 31.5 | 13.0 | 12.4 |
MrOS (USA) Year 4g | 43h | 12 | 12 |
n = 1994 participants.
n = 788 participants.
n = 1996 participants.
n = 295 participants.
n = 1546 participants.
n = 1519 participants.
n = 190 participants.
Estimated from baseline data plus de novo number. The F:M ratio of MsOS (Hong Kong) and MrOS (Hong Kong) is 1.3:1 while the F:M ratio of MsOS (USA) and MrOS (USA) is 1.38:1.